Just my guess, but I also think that NGIO represents a separation from Generex in terms of a potential future accusation. That is, since it seems to be the cancer portion (AE37) of what they do, a future company (MRK perhaps) would just need to gobble up what they are only interested in once they see the results that they want to see, and not have to get involved with all the other ancillary stuff that Generex is involved with.